Med2Date — Clinical Guidelines
Home Immunology T Cell Deficiency

T Cell Deficiency

Last updated 31 May 2026 · Immunology clinical guideline

📋 Key Information Summary

📋
  • T cell deficiency impairs cell-mediated immunity, predisposing to opportunistic infections by intracellular pathogens, fungi, and certain viruses
  • Primary causes include severe combined immunodeficiency (SCID), DiGeorge syndrome (22q11.2 deletion), and combined variable immunodeficiency (CVID)
  • Secondary causes are dominated by HIV/AIDS, corticosteroid therapy, post-transplant immunosuppression, and chemotherapy
  • Absolute CD4+ T cell count is the principal marker of T cell competence; <200 cells/μL defines severe deficiency in HIV
  • Presenting infections include Pneumocystis jirovecii pneumonia (PCP), mucocutaneous candidiasis, CMV disease, and mycobacterial infections
  • Investigation pathway: full blood count with lymphocyte subsets, flow cytometry, HIV serology, and functional T cell assays
  • Newborn screening for SCID using T cell receptor excision circles (TRECs) is performed in all Australian states via Guthrie cards
  • PCP prophylaxis with trimethoprim–sulfamethoxazole is indicated when CD4 <200 cells/μL in HIV and in other severely immunosuppressed patients
  • Live vaccines (MMR, varicella, BCG, oral polio, Yellow Fever) are generally contraindicated in significant T cell deficiency
  • Antiretroviral therapy (ART) is the cornerstone of management for HIV-related T cell deficiency; early initiation improves outcomes
  • Haematopoietic stem cell transplantation (HSCT) is curative for SCID and other severe primary immunodeficiencies
  • Aboriginal and Torres Strait Islander peoples have disproportionately higher HIV and TB rates, requiring culturally safe screening and management
  • Immunology and infectious diseases referral is recommended for all patients with confirmed primary T cell deficiency

Introduction & Australian Epidemiology

T cell deficiency impairs cell-mediated immunity, the arm of the adaptive immune system responsible for defence against intracellular pathogens, fungi, and certain viruses. Deficiency may be primary (genetic/congenital) or secondary (acquired), and the clinical severity ranges from mild susceptibility to infections in partial deficiency to life-threatening opportunistic disease in severe deficiency.

In Australia, secondary T cell deficiency — particularly HIV/AIDS and iatrogenic immunosuppression — accounts for the vast majority of cases encountered in clinical practice. As of 2023, approximately 29,460 people were living with HIV in Australia, with an estimated 90% diagnosed, 91% of those on antiretroviral therapy, and 97% of those virally suppressed (Kirby Institute, 2023). Despite these strong national outcomes, late diagnosis remains a concern, with approximately one-third of new diagnoses presenting with a CD4 count <350 cells/μL.

Primary immunodeficiencies (PIDs) affecting T cells are rare but important. Severe combined immunodeficiency (SCID) affects approximately 1 in 50,000–70,000 live births. Since 2018, newborn screening for SCID via T cell receptor excision circles (TRECs) on Guthrie cards has been progressively implemented across Australian states and territories, enabling early detection and life-saving intervention.

DiGeorge syndrome (22q11.2 deletion syndrome) affects approximately 1 in 4,000 live births and may present with a spectrum of T cell impairment ranging from complete absence (complete DiGeorge) to mild lymphopenia that improves with age (partial DiGeorge).

Iatrogenic T cell suppression — from corticosteroids, calcineurin inhibitors, anti-thymocyte globulin, rituximab, and various chemotherapeutic agents — is increasingly encountered as transplant medicine, oncology, and rheumatology therapeutic programmes expand in Australia.

T Cell Deficiency clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — T Cell Deficiency: pathophysiology, clinical clues, diagnosis, imaging, and management.
T Cell Deficiency infographic, full size

Causes & Classification

T cell deficiency is classified broadly as primary (inherited/congenital) or secondary (acquired). The classification guides investigation, prognosis, and management strategy.

Primary T Cell Deficiency

Condition Genetic Basis Inheritance Key Features
Severe Combined Immunodeficiency (SCID) IL2RG, JAK3, RAG1/2, ADA, IL7Rα, CD3δ/ε/ζ, Artemis mutations X-linked or AR Absent T cells (±B/NK cells); presents in infancy with failure to thrive, opportunistic infections; universally fatal without HSCT
DiGeorge Syndrome (22q11.2 deletion) 22q11.2 microdeletion De novo (90%) or AD Thymic hypoplasia/aplasia; spectrum from complete absence of T cells (complete DiGeorge) to mild lymphopenia; associated cardiac anomalies, hypocalcaemia, facial dysmorphism
Combined Variable Immunodeficiency (CVID) Heterogeneous; ICOS, TACI, BAFFR, CD19 Usually sporadic; AR/AD forms Hypogammaglobulinaemia with impaired T cell function; typically presents in 2nd–4th decade; recurrent sinopulmonary infections, autoimmunity
Wiskott–Aldrich Syndrome WAS gene (Xp11.22) X-linked Eczema, thrombocytopenia, combined immunodeficiency; progressive T cell decline
Ataxia Telangiectasia ATM gene AR Progressive cerebellar ataxia, telangiectasia, combined immunodeficiency, cancer predisposition
Hyper-IgM Syndromes CD40LG, CD40, AID, UNG X-linked or AR Defective class-switch recombination; low IgG/IgA with elevated IgM; susceptibility to Pneumocystis, Cryptosporidium
DOCK8 Deficiency DOCK8 AR Severe eczema, recurrent viral skin infections, combined immunodeficiency, elevated IgE

Secondary (Acquired) T Cell Deficiency

Cause Mechanism Clinical Context
HIV infection CD4+ T cell destruction by HIV; immune activation and exhaustion Most common cause of T cell deficiency in Australia; ~29,460 people living with HIV (2023)
Corticosteroids T cell apoptosis, reduced IL-2 production, lymphocyte redistribution Risk increases with doses >20 mg/day prednisolone equivalent for >2 weeks
Calcineurin inhibitors Block IL-2 transcription (cyclosporin, tacrolimus) Solid organ and stem cell transplant recipients
Anti-thymocyte globulin (ATG) T cell depletion via antibody-mediated cytotoxicity Induction therapy in transplantation; aplastic anaemia treatment
Chemotherapy Cytotoxic to rapidly dividing lymphocytes Fludarabine, cladribine, alemtuzumab particularly lymphodepletive
Biologics (rituximab, anti-TNFα) B cell depletion (indirect T cell dysfunction); TNF blockade impairs granuloma formation Rheumatoid arthritis, IBD, lymphoma, vasculitis
Malnutrition Thymic atrophy, reduced lymphopoiesis Protein-energy malnutrition, anorexia nervosa, critical illness
Malignancy T cell lymphoma, thymoma, bone marrow infiltration Direct tumour effect on thymus or lymphoid tissue
Chronic viral infections (CMV, EBV) T cell exhaustion and immune senescence Post-transplant, chronic immunosuppression
⚠️
Key clinical distinction: Primary T cell deficiency typically presents in infancy or early childhood and requires early immunology referral. Secondary T cell deficiency is far more common in adult practice, and the degree of immunosuppression should be quantified (CD4 count, duration of therapy) to guide prophylaxis decisions.

Clinical Features

The clinical presentation of T cell deficiency varies with the severity of T cell impairment and whether associated B cell or antibody deficiency is present. Patients with predominantly T cell dysfunction are susceptible to a characteristic spectrum of infections, while those with combined defects present with broader infectious and non-infectious manifestations.

Infectious Presentations by T Cell Count

Mild
CD4 200–500 cells/μL
Recurrent mucocutaneous candidiasis (oral thrush, vaginal candidiasis), herpes zoster reactivation, prolonged viral illnesses, mild bacterial infections
Setting: Primary care management; monitor CD4 trajectory
Moderate
CD4 50–200 cells/μL
Pneumocystis jirovecii pneumonia (PCP), oesophageal candidiasis, disseminated HSV, oral hairy leucoplakia (EBV), cerebral toxoplasmosis, cryptococcal meningitis
Setting: Specialist initiation of prophylaxis; immunology/ID referral
Severe
CD4 <50 cells/μL
Disseminated Mycobacterium avium complex (MAC), CMV retinitis/colitis/pneumonitis, progressive multifocal leucoencephalopathy (PML/JC virus), primary CNS lymphoma (EBV-related), cryptosporidiosis
Setting: Hospital-level care; tertiary immunology/infectious diseases

Pathogen-Specific Susceptibilities

Pathogen Category Specific Organisms Clinical Syndromes
Fungi Candida spp., Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides spp. Oropharyngeal/oesophageal candidiasis, cryptococcal meningitis, disseminated histoplasmosis
Opportunistic protozoa Toxoplasma gondii, Cryptosporidium spp., Microsporidium spp. Cerebral toxoplasmosis, chronic diarrhoea, cholangiopathy
Viruses CMV, HSV, VZV, EBV, JC virus, HHV-8 CMV retinitis/colitis, severe mucocutaneous HSV, disseminated VZV, PML, Kaposi sarcoma
Mycobacteria M. tuberculosis, M. avium complex (MAC) Disseminated TB, MAC bacteraemia, chronic pulmonary disease
Bacteria Pneumocystis jirovecii (classified as fungus), Listeria monocytogenes, Nocardia spp., Salmonella spp. PCP pneumonia, listeria meningitis/bacteraemia, nocardiosis, recurrent salmonella bacteraemia

Non-Infectious Features

  • Failure to thrive (infants with SCID or DiGeorge)
  • Chronic diarrhoea and malabsorption
  • Autoimmune phenomena — particularly in CVID, IPEX, and DiGeorge syndrome
  • Eczematous dermatitis — DOCK8 deficiency, Wiskott–Aldrich syndrome
  • Malignancy — lymphoma (EBV-associated), Kaposi sarcoma (HHV-8)
  • Graft-versus-host disease — in SCID following non-irradiated blood transfusion (transfusion-associated GVHD)
  • Congenital anomalies — cardiac defects, hypocalcaemia, facial dysmorphism (DiGeorge)
🚨
Critical safety warning — Transfusion-associated GVHD: Patients with suspected or confirmed SCID or complete DiGeorge syndrome must receive irradiated blood products only. Non-irradiated transfusions can cause fatal transfusion-associated graft-versus-host disease. Irradiated blood products must be requested via the Australian Red Cross LifeBlood service.

Investigations

Investigation of T cell deficiency follows a stepwise approach from basic blood tests to specialised functional and genetic studies. The depth of investigation is guided by clinical suspicion of primary versus secondary deficiency.

Initial Screening Tests

Essential
Full blood count with differential and lymphocyte subsets
Absolute lymphocyte count (ALC) <1,500 cells/μL in adults or age-adjusted paediatric thresholds warrants further investigation. Lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, CD16/56+) via flow cytometry. MBS item 65070.
Essential
HIV serology (4th-generation Ag/Ab combination assay)
Mandatory in any patient with unexplained T cell lymphopenia or opportunistic infection. MBS item 69312 (initial screen). Fourth-generation assay detects HIV-1 p24 antigen and HIV-1/HIV-2 antibodies simultaneously.
Available
Serum immunoglobulins (IgG, IgA, IgM, IgE)
To identify combined immunodeficiency. CVID, hyper-IgM, and X-linked agammaglobulinaemia may present with concurrent humoral deficiency. MBS item 65070.
Available
Chest X-ray (thymic shadow assessment)
Absent thymic shadow in infancy is suggestive of SCID or complete DiGeorge syndrome. MBS item 58500.

Specialised / Confirmatory Investigations

Specialist
T cell receptor excision circles (TRECs) — newborn screening
Performed on Guthrie card dried blood spot. Low/absent TRECs indicate impaired thymic output. Available across Australian states via neonatal screening programmes. Free as part of newborn screening.
Specialist
Intracellular cytokine staining / T cell proliferation assays
Functional T cell assessment. PHA, ConA, and anti-CD3 stimulation to assess proliferative capacity. Available at specialised immunology laboratories (e.g., Royal Children's Hospital Melbourne, Westmead Hospital Sydney).
Specialist
Genetic testing — targeted gene panels and whole-exome sequencing (WES)
Definitive diagnosis for primary immunodeficiency. Available through accredited Australian clinical genetics laboratories (e.g., Victorian Clinical Genetics Services, SA Pathology). MBS item 73287 (genomic sequencing for targeted conditions).
Available
Delayed-type hypersensitivity (DTH) skin testing
Candida, tetanus, tuberculin (Mantoux) antigens. Anergy panel — failure to react to any antigen suggests impaired cell-mediated immunity. Widely available in primary care.
Available
Quantitative immunoglobulins and vaccine response
Pre- and post-vaccination titres (tetanus, pneumococcal serotypes) to assess functional antibody production in combined immunodeficiency. MBS item 65070.
Referral
FISH for 22q11.2 deletion / chromosomal microarray
Confirmatory for DiGeorge syndrome. Chromosomal microarray (CMA) is now the first-line test for developmental delay and intellectual disability (replaces karyotype in many contexts). Available through clinical genetics services.

Age-Adjusted Normal Lymphocyte Counts

Age Total Lymphocytes (cells/μL) CD3+ T cells (cells/μL) CD4+ T cells (cells/μL)
Birth 2,000–11,000 1,500–6,000 1,000–4,000
2–6 months 2,500–16,500 2,000–10,000 1,400–7,000
1–2 years 2,000–10,000 1,500–7,000 1,000–5,000
6–12 years 1,500–6,000 1,000–3,500 600–2,500
Adult 1,000–4,800 700–2,100 400–1,500

Management

Management of T cell deficiency encompasses treatment of underlying causes, opportunistic infection prophylaxis and treatment, immune reconstitution, vaccination modifications, and specialist referral. The approach differs substantially between primary and secondary deficiency.

Antimicrobial Prophylaxis

Prophylaxis is targeted to the CD4 count and the specific pathogen risks. The following regimens align with Australian Therapeutic Guidelines and national HIV management guidelines.

💊
Trimethoprim–Sulfamethoxazole (Co-trimoxazole)
Bactrim® · Resprim® · Antimicrobial (dihydrofolate reductase inhibitor)
Adult dose Single-strength tablet (TMP 80 mg/SMX 400 mg) PO daily; or double-strength 3× per week (Mon/Wed/Fri)
Paediatric dose 5 mg/kg/day (TMP component) PO daily (max 320 mg TMP/day); suspension available
Indication PCP prophylaxis when CD4 <200 cells/μL; also covers Toxoplasma and some bacterial infections
Renal adjustment Reduce dose if CrCl <30 mL/min; avoid if CrCl <15 mL/min
PBS status ✔ PBS General Benefit
💊
Azithromycin
Zithromax® · Azithrobell® · Macrolide antibiotic
Adult dose 1,200 mg PO once weekly (for MAC prophylaxis)
Paediatric dose 20 mg/kg once weekly (max 1,200 mg) for MAC prophylaxis
Indication MAC prophylaxis when CD4 <50 cells/μL in HIV
Renal adjustment No adjustment required; use with caution in severe renal impairment
PBS status ✔ PBS General Benefit
💊
Fluconazole
Diflucan® · Ozole® · Triazole antifungal
Adult dose 100–200 mg PO daily for secondary prophylaxis of oesophageal candidiasis or cryptococcal meningitis consolidation
Paediatric dose 3–6 mg/kg PO daily (max 200 mg/day)
Renal adjustment Reduce dose by 50% if CrCl <50 mL/min
PBS status ✔ PBS General Benefit
💊
Valganciclovir
Valcyte® · Livalo® (CMV) · Guanosine analogue
Adult dose 900 mg PO daily with food (CMV prophylaxis); 900 mg PO BD for 21 days then 900 mg daily (CMV treatment)
Paediatric dose Dose based on BSA and creatinine clearance; specialist guidance required
Renal adjustment Dose reduction required for CrCl <60 mL/min; haemodialysis dose available
PBS status ⚠ PBS Restricted Benefit — CMV disease in immunocompromised patients

Antiretroviral Therapy (HIV-Related T Cell Deficiency)

ART is the cornerstone of immune reconstitution in HIV. Current Australian guidelines recommend initiation of ART in all people diagnosed with HIV, regardless of CD4 count (ASHM, 2024). Preferred first-line regimens for treatment-naïve adults include:

💊
Bictegravir / Emtricitabine / Tenofovir alafenamide
Biktarvy® · INSTI + NRTI backbone
Adult dose One tablet (BIC 50 mg / FTC 200 mg / TAF 25 mg) PO once daily with or without food
Renal adjustment Not recommended if CrCl <30 mL/min (TAF component)
PBS status ⚠ PBS Authority Required
💊
Dolutegravir / Lamivudine
Dovato® · INSTI + NRTI
Adult dose One tablet (DTG 50 mg / 3TC 300 mg) PO once daily
Renal adjustment Not recommended if CrCl <50 mL/min
PBS status ⚠ PBS Authority Required
ℹ️
Immune reconstitution inflammatory syndrome (IRIS): Paradoxical worsening of pre-existing infections (e.g., TB, MAC, cryptococcosis) may occur 1–12 weeks after initiating ART, particularly in patients with low baseline CD4 counts (<100 cells/μL). Pre-existing opportunistic infections should be treated before or concurrently with ART initiation. Consult infectious diseases specialist for IRIS management.

Curative Therapies for Primary T Cell Deficiency

1
Haematopoietic Stem Cell Transplantation (HSCT)
Curative for SCID, Wiskott–Aldrich syndrome, and other severe combined immunodeficiencies. Best outcomes with early transplant (<3.5 months of age for SCID). Available at paediatric transplant centres: Royal Children's Hospital Melbourne, Sydney Children's Hospital Westmead, Women's and Children's Hospital Adelaide, Queensland Children's Hospital Brisbane.
2
Gene Therapy
Available for ADA-SCID (Strimvelis® approved in EU; clinical trials available in Australia). X-linked SCID and Wiskott–Aldrich gene therapy in clinical trials. Contact state-level gene therapy programmes for eligibility.
3
Thymus Transplantation
Indicated for complete DiGeorge syndrome (athymic). Cultured thymic tissue transplant programmes exist internationally; not currently available in Australia. Referral to international centres (e.g., Duke University, USA) may be considered.

Vaccination Considerations

⚠️
Live vaccine contraindications: The following live vaccines are contraindicated in patients with significant T cell deficiency (CD4 <200 cells/μL or known primary T cell immunodeficiency):
  • MMR (measles, mumps, rubella) — except in asymptomatic HIV with CD4 ≥200
  • Varicella (unless CD4 ≥200 and asymptomatic HIV)
  • BCG (Bacillus Calmette–Guérin)
  • Oral polio (Sabin) — use IPV (inactivated) instead
  • Yellow Fever
  • Rotavirus
  • Oral typhoid (Ty21a)

Household contacts should receive influenza vaccination annually and ensure up-to-date MMR, varicella, and pertussis vaccination to create a cocoon of protection. COVID-19 vaccination (mRNA-based, not live) is recommended and safe in T cell-deficient patients.

Immunoglobulin Replacement

If T cell deficiency is accompanied by hypogammaglobulinaemia or impaired antibody production (e.g., CVID, hyper-IgM syndromes), immunoglobulin replacement therapy (IgRT) is indicated:

  • IVIg: 400–600 mg/kg every 3–4 weeks (PBS Authority Required)
  • SCIg: 100–200 mg/kg per week subcutaneous infusion (home-based programme available via immunology departments)

MBS item 13705 covers IVIg administration in hospital settings; MBS item 13711 for SCIg home administration training.

Special Populations

🤰 Pregnancy
ART in pregnancy
ART must be continued throughout pregnancy to prevent vertical HIV transmission. Preferred regimens in Australia: DTG-based or RAL-based (with FTC/TAF backbone). Avoid dolutegravir if initiating in first trimester only if alternative available (though 2024 data supports safety). Zidovudine (AZT) no longer routinely required. Planned Caesarean section if viral load >1,000 copies/mL at 36 weeks.
Live vaccines
Avoid live vaccines in pregnancy, even in immunocompetent women (standard guidance). Postpartum MMR can be given if CD4 adequate.
Tenofovir alafenamide
Preferred over TDF in pregnancy for reduced renal and bone toxicity. Compatible with breastfeeding in Australia (PBAC, 2023 guidance).
👶 Paediatrics
SCID — newborn screening
TREC assay on Guthrie card detects >90% of SCID cases. Positive TREC → urgent lymphocyte subsets and immunology referral. Target HSCT <3.5 months of age for optimal outcome. Irradiated blood products mandatory until SCID excluded.
DiGeorge syndrome
Assess cardiac anatomy (echocardiography), calcium levels (hypoparathyroidism), and T cell subsets. Partial DiGeorge may improve spontaneously with thymic maturation. Complete DiGeorge requires urgent transplant evaluation.
Trimethoprim–sulfamethoxazole
Available as paediatric suspension. Dose: 5 mg/kg/day TMP component. Monitor for neutropenia and hyperkalaemia.
👴 Elderly
Immunosenescence
Age-related thymic involution reduces naive T cell output. Combined with chronic infections (CMV) and comorbidities, elderly patients have reduced T cell diversity and impaired vaccine responses. Lower threshold for PCP prophylaxis in prolonged immunosuppressive therapy.
Medication interactions
Polypharmacy is common. Trimethoprim can cause hyperkalaemia with ACE inhibitors/ARBs. Fluconazole interacts with warfarin, statins, and phenytoin. Check interaction databases (Australian Medicines Handbook) before prescribing.
🫘 Renal Impairment
Dose adjustments required
Trimethoprim–sulfamethoxazole: reduce dose if CrCl <30 mL/min; avoid if <15 mL/min. Valganciclovir: significant dose reductions for CrCl <60 mL/min. Acyclovir/valaciclovir: dose reduce in renal impairment. Monitor renal function closely with all antivirals and antimicrobials.
Dialysis patients
Tenofovir alafenamide preferred over TDF in dialysis. Ganciclovir IV preferred over valganciclovir in severe renal impairment for CMV treatment.
🫁 Hepatic Impairment
ART considerations
Hepatitis B co-infection: ensure ART regimen includes anti-HBV agents (TAF, TDF, FTC, 3TC) to avoid HBV flare on withdrawal. Monitor LFTs closely. Avoid nevirapine in Child–Pugh B/C. Ritonavir-boosted regimens require caution in severe hepatic impairment.
Antifungal agents
Itraconazole and voriconazole require caution and dose adjustment in hepatic impairment. Fluconazole is generally safer in mild–moderate hepatic disease.
🛡️ Immunocompromised (Non-HIV)
Transplant recipients
Solid organ and HSCT recipients on calcineurin inhibitors, mycophenolate, and/or sirolimus have variable T cell suppression. PCP prophylaxis typically for 6–12 months post-transplant (longer in lung transplant or ongoing immunosuppression). CMV prophylaxis or preemptive therapy per transplant unit protocol.
Rheumatology/IBD patients
TNFα inhibitors (adalimumab, infliximab) increase risk of TB reactivation — screen with IGRA (QuantiFERON-TB Gold Plus) before commencing. Screen for hepatitis B. Avoid live vaccines while on biologics.
Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of infections that are exacerbated by T cell deficiency. Culturally safe, trauma-informed care is essential in all clinical encounters.

HIV epidemiology
Aboriginal and Torres Strait Islander peoples are diagnosed with HIV at approximately twice the rate of non-Indigenous Australians. Late diagnosis (CD4 <350) is more common, reflecting barriers to testing and healthcare access. Tailored testing strategies — including community-based point-of-care testing (e.g., Dried Blood Spot testing programme) — are critical.
Tuberculosis
TB rates in Aboriginal and Torres Strait Islander peoples are 6–8 times higher than in non-Indigenous Australians, with higher rates in remote communities (Northern Territory, Far North Queensland). TB is more likely to present with extrapulmonary disease in immunosuppressed patients. RHDAustralia guidelines should be followed for screening and management.
Remote and rural access
Access to immunology and infectious diseases specialists is limited in remote Australia. Telehealth consultations are available via Medicare items (MBS item 91822). CD4 monitoring requires reliable pathology collection — outreach pathology services and point-of-care CD4 testing (PIMA analyser) are available through some Aboriginal Community Controlled Health Services (ACCHS).
BCG vaccination
BCG is recommended for Aboriginal and Torres Strait Islander neonates in areas with high TB incidence (NT, parts of QLD, WA). However, BCG is contraindicated in confirmed or suspected primary immunodeficiency (including SCID). TREC newborn screening for SCID should be completed before BCG administration when possible.
Cultural safety
Engage Aboriginal and Torres Strait Islander Health Workers and Liaison Officers. Use culturally appropriate communication (e.g., avoid direct eye contact if culturally inappropriate). Ensure gender-concordant care where preferred. Acknowledge the Stolen Generations and ongoing impacts on healthcare engagement. Support patient choice of provider and location of care.
Social determinants
Overcrowded housing, food insecurity, and limited access to clean water in remote communities increase infection risk in T cell-deficient patients. Partner with social workers and community services to address housing, nutrition, and medication access (Closing the Gap PBS co-payment measure).

📚 References

  1. 1. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2023. Sydney: UNSW Sydney; 2023.
  2. 2. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Antiretroviral guidelines: Australian commentary on the US DHHS guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ASHM; 2024.
  3. 3. National Health and Medical Research Council (NHMRC). Australian immunisation handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  4. 4. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol. 2022;42(7):1508–1520.
  5. 5. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–738.
  6. 6. Australian Institute of Health and Welfare (AIHW). HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report. Canberra: AIHW; 2023.
  7. 7. RHDAustralia (a programme of Menzies School of Health Research). NT Tuberculosis Procedures Manual. Darwin: NT Department of Health; 2022.
  8. 8. Lucas M, Hughes WJ, Kwan A, et al. Newborn screening for severe combined immunodeficiency: what are we waiting for? Ann Allergy Asthma Immunol. 2023;130(4):427–433.
  9. 9. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973–980.
  10. 10. Parker SK, Harding JL. Newborn screening for SCID: what comes next? Immunol Allergy Clin North Am. 2020;40(3):497–512.
  11. 11. Australasian Society of Clinical Immunology and Allergy (ASCIA). Primary immunodeficiency diseases: position statements and guidelines. ASCIA; 2024. Available from: allergy.org.au.
  12. 12. Department of Health and Aged Care, Australian Government. National Aboriginal and Torres Strait Islander Health Plan 2021–2031. Canberra: Commonwealth of Australia; 2021.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).